Summary
Biogen Inc. reported a slight increase in total revenues for the first quarter of 2020, reaching $3.53 billion compared to $3.49 billion in the same period of 2019. This growth was primarily driven by a robust 8.4% increase in product revenues, totaling $2.90 billion, with notable contributions from its Multiple Sclerosis (MS) franchise, particularly the Fumarate products (TECFIDERA and VUMERITY), and a significant uptick in biosimilar sales. Despite a decline in 'Other Revenues,' largely due to a prior year inventory sale, overall revenue growth was supported by the company's core therapeutic areas. Diluted earnings per share (EPS) saw a healthy increase of 13.0% to $8.08, reflecting improved operational efficiency and a lower effective tax rate compared to the prior year. Operationally, Biogen demonstrated improved cost management with total costs and expenses decreasing by 13.7%. This reduction was driven by lower cost of sales and R&D expenses, partly offset by increased collaboration profit sharing. The company also made significant capital allocation decisions, repurchasing approximately $2.2 billion of its common stock during the quarter, signaling a commitment to returning value to shareholders. Management anticipates ongoing challenges and opportunities related to market dynamics, competition, and the evolving impact of the COVID-19 pandemic on its business operations and clinical trials.
Financial Highlights
52 data points| Revenue | $3.53B |
| Cost of Revenue | $454.30M |
| Gross Profit | $3.08B |
| SG&A Expenses | $570.10M |
| Operating Expenses | $1.71B |
| Operating Income | $1.82B |
| Interest Expense | $44.30M |
| Net Income | $1.40B |
| EPS (Basic) | $8.10 |
| EPS (Diluted) | $8.08 |
| Shares Outstanding (Basic) | 172.80M |
| Shares Outstanding (Diluted) | 173.10M |
Key Highlights
- 1Total revenues increased by 1.3% to $3.53 billion in Q1 2020, driven by product revenue growth.
- 2Product revenues grew by 8.4% to $2.90 billion, with strong performance in MS products (Fumarate and Tysabri) and biosimilars.
- 3Diluted EPS increased by 13.0% to $8.08, reflecting operational improvements and a lower tax rate.
- 4Total costs and expenses decreased by 13.7% to $1.71 billion, primarily due to lower cost of sales and R&D expenses.
- 5Biogen repurchased approximately $2.2 billion of its common stock in Q1 2020, demonstrating capital return to shareholders.
- 6The company acquired BIIB118 from Pfizer for potential treatment of neurological symptoms in Alzheimer's and Parkinson's diseases.
- 7The company noted potential impacts from the COVID-19 pandemic on sales, clinical trials, and supply chains, while also observing some accelerated sales due to precautionary measures.